Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 4/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.77 |
| ▸ | RECQL | P46063 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | STS | P08842 | 9/20 | 0.69 |
| ▸ | ESR1 | P03372 | 3/20 | 0.68 |
| ▸ | CA1 | P00915 | 3/20 | 0.68 |
| ▸ | CA2 | P00918 | 3/20 | 0.68 |
| ▸ | CA9 | Q16790 | 3/20 | 0.68 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.68 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.68 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.68 |
| ▸ | CA4 | P22748 | 1/20 | 0.68 |
| ▸ | CA6 | P23280 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7755033 | 0.91 | HSD17B1 (0.74) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL10134113 | 0.91 | HSD17B1 (0.74) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL6700171 | 0.91 | HSD17B1 (0.78) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL6691697 | 0.91 | HSD17B1 (0.74) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL11672003 | 0.91 | HSD17B1 (0.74) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL14044784 | 0.91 | HSD17B1 (0.74) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL6694124 | 0.90 | KDM4E (0.71) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL9633204 | 0.89 | KDM4E (0.75) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL14377634 | 0.89 | KDM4E (0.72) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL11671118 | 0.88 | HSD17B1 (0.78) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082556-A1 | Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use | ENDORECHERCHE, INC. | 2004-04-29 | — | — | US | disclosed |
| EP-1321146-A2 | Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use | Endorecherche Inc. (CA) | 2003-06-25 | — | — | EP | disclosed |
| US-6541463-B1 | 17-spirolactone derivatives of steroids | ENDORECHERCHE, INC. (CA) | 2003-04-01 | — | — | US | disclosed |
| EP-1094798-A2 | INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | Endorecherche Inc. (CA) | 2001-05-02 | — | — | EP | disclosed |
| WO-1999046279-A2 | INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | ENDORECHERCHE, INC. (CA) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082556-A1 | Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use | HSD17B11, HSD17B3, HSD17B1 | HSD17B1 3/4885LMNA 3211/4885MAPT 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.